-
1 Comment
MedMira Inc is currently in a long term downtrend where the price is trading 37.0% below its 200 day moving average.
From a valuation standpoint, the stock is 95.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 65.8.
MedMira Inc's total revenue rose by 1587.0% to $2M since the same quarter in the previous year.
Its net income has increased by 216.4% to $715K since the same quarter in the previous year.
Finally, its free cash flow grew by 11.8% to $-363K since the same quarter in the previous year.
Based on the above factors, MedMira Inc gets an overall score of 4/5.
ISIN | CA58501R1029 |
---|---|
Exchange | F |
CurrencyCode | EUR |
Sector | Healthcare |
Industry | Biotechnology |
PE Ratio | None |
---|---|
Target Price | None |
Beta | 14.15 |
Market Cap | 44M |
Dividend Yield | None |
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and REVEALCOVID-19 and Reveal G4 HIV tests. The company distributes its products through a network of medical distributors and strategic business development partners, serving customers in various healthcare sectors, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 47M.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025